Zyrtec Pediatric Efficacy
Children’s ZYRTEC® makes a significant impact on allergy symptoms1*
Powerful symptom responses in pediatric patients with seasonal allergic rhinitis (SAR)1
Efficacy in ages 2 to 6
66% of children demonstrated ≥50% improvement from baseline SAR symptoms over 2 weeks.1
Children’s ZYRTEC® 5 mg: Improvement in SAR Symptoms1*
QHS=every night
Efficacy in ages 6 to 11
37% and 19% of children demonstrated ≥50% improvement from baseline SAR symptoms over 2 weeks.1
Children’s ZYRTEC® 10 mg: Improvement in SAR Symptoms Over 2 Weeks1§
QAM=every morning
*Randomized, placebo-controlled study of children ages 2 to 6 years with SAR during a 2-week period. Primary endpoint was the change in total symptom score complex from baseline.
†Significant vs placebo.
‡ZYRTEC® 5 mg vs placebo ratio at ≥50% reduction is 1.84-fold.
§Randomized, placebo-controlled studies of children ages 6 to 11 years with SAR during a 2-week period. Primary endpoint was the change in total symptom score complex from baseline.
||ZYRTEC® 10 mg vs placebo ratio at ≥50% reduction is 1.88-fold in Study 1 and 1.42-fold in Study 2.
Reference:
1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
Related articles
